Opinion

Preclinical autoimmune disease biotech Design Therapeutics files for a $100 million IPO

Design Therapeutics, a preclinical biotech developing gene targeted chimeras for nucleotide expansion diseases, filed on Friday with the SEC to raise …

Read more

Show More

Related Articles